Vendel A. Kristensen
- Consultant, Postdoc; MD
Education:
- MD University of Bergen (2001)
- PhD University of Oslo (2016)
- Norwegian clinical specialist accreditations: Internal medicine (2012) and gastroenterology (2017)
Current position:
Consultant, Department of gastroenterology, Oslo University Hospital
Publications 2024
Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)
J Crohns Colitis (in press)
DOI 10.1093/ecco-jcc/jjae170, PubMed 39527064
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study
Inflamm Bowel Dis (in press)
DOI 10.1093/ibd/izae297, PubMed 39699202
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply
Aliment Pharmacol Ther, 60 (6), 831-832
DOI 10.1111/apt.18187, PubMed 39072820
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408
Publications 2023
Intraoperative distensibility measurement in POEM for achalasia: impact on patient outcome and associations with other outcome variables at 1-year follow-up
Surg Endosc, 37 (12), 9283-9290
DOI 10.1007/s00464-023-10494-z, PubMed 37880446
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
J Crohns Colitis, 17 (11), 1781-1790
DOI 10.1093/ecco-jcc/jjad094, PubMed 37279652
Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
BMC Gastroenterol, 23 (1), 255
DOI 10.1186/s12876-023-02889-y, PubMed 37501083
Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
Qual Life Res, 32 (10), 2951-2964
DOI 10.1007/s11136-023-03435-9, PubMed 37219727
Publications 2022
Quality of life in patients with achalasia: Associations with Eckardt score and objective treatment outcomes after peroral endoscopic myotomy
Endosc Int Open, 10 (12), E1570-E1576
DOI 10.1055/a-1968-7682, PubMed 36531682
Publications 2021
One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy
Ann Med, 53 (1), 2225-2233
DOI 10.1080/07853890.2021.2005253, PubMed 34806501
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494
Publications 2020
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542
Publications 2019
Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
Scand J Gastroenterol, 54 (1), 1-7
DOI 10.1080/00365521.2018.1549271, PubMed 30650313
Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease
Scand J Gastroenterol, 54 (5), 571-576
DOI 10.1080/00365521.2019.1608467, PubMed 31050907
Publications 2017
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol Res Pract, 2017, 2098293
DOI 10.1155/2017/2098293, PubMed 29225617
Publications 2016
Patient-performed extraction of faecal calprotectin
Clin Chem Lab Med, 54 (8), 1357-63
DOI 10.1515/cclm-2015-1037, PubMed 26812797
Publications 2015
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
J Crohns Colitis, 9 (2), 164-9
DOI 10.1093/ecco-jcc/jju015, PubMed 25518057
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand J Clin Lab Invest, 75 (5), 355-61
DOI 10.3109/00365513.2015.1030765, PubMed 25856663
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand J Gastroenterol, 51 (5), 548-55
DOI 10.3109/00365521.2015.1117650, PubMed 26634305
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand J Gastroenterol, 50 (9), 1183-4
DOI 10.3109/00365521.2015.1025830, PubMed 25772406